Latest Hematological malignancy Stories
CLL is second indication approved by FDA for ibrutinib; previously approved for mantle cell lymphoma patients WHITE PLAINS, N.Y., Feb. 12, 2014 /PRNewswire/ -- Today's U.S.
SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S.
-- Study Focused on Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who are EphA3 Positive -- SOUTH SAN FRANCISCO, Calif., Feb.
Kurt Jacquin, Owner of SuperSlow Zone in San Antonio, TX is proud to support the Leukemia and Lymphoma Society, a not-for-profit organization dedicated to funding blood cancer research and providing
BURLINGAME, Calif., Feb. 4, 2014 /PRNewswire/ -- Cleave Biosciences today announced Alessandra Cesano, M.D., Ph.D. has joined the company as Chief Medical Officer. Dr.
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system.
In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML).
Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease.
Grant Program Addresses Three Critical Areas of Blood Cancer Research WHITE PLAINS, N.Y., Jan.
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.